|
STARD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62769797640294E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.15405471237773E-12 |
| Normal-vs-Stage2 |
2.22780000003198E-06 |
| Normal-vs-Stage3 |
8.91609008846217E-12 |
| Normal-vs-Stage4 |
5.78936898421034E-12 |
| Stage1-vs-Stage2 |
4.314200E-01 |
| Stage1-vs-Stage3 |
6.488000E-01 |
| Stage1-vs-Stage4 |
4.626000E-02 |
| Stage2-vs-Stage3 |
2.771600E-01 |
| Stage2-vs-Stage4 |
3.961900E-02 |
| Stage3-vs-Stage4 |
1.927220E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.66533453693773E-15 |
| Normal-vs-AfricanAmerican |
1.92490999999517E-05 |
| Normal-vs-Asian |
1.17389997722483E-09 |
| Caucasian-vs-AfricanAmerican |
7.166600E-01 |
| Caucasian-vs-Asian |
8.492800E-01 |
| AfricanAmerican-vs-Asian |
6.290600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.74520456051187E-11 |
| Normal-vs-Female |
1.63258295771129E-12 |
| Male-vs-Female |
7.832800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.96939950195485E-10 |
| Normal-vs-Age(41-60Yrs) |
6.60582699651968E-14 |
| Normal-vs-Age(61-80Yrs) |
1.65199964818896E-10 |
| Normal-vs-Age(81-100Yrs) |
4.254300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.614600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.519000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.297400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.750200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.071800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.987370E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.414600E-01 |
| Classical-VS-Follicular |
7.655800E-02 |
| Classical-VS-Other |
2.076000E-01 |
| Classical-VS-Normal |
4.97889507400373E-11 |
| Tall-VS-Follicular |
9.047800E-02 |
| Tall-VS-Other |
2.138200E-01 |
| Tall-VS-Normal |
9.49420000395662E-08 |
| Follicular-VS-Other |
5.360900E-03 |
| Follicular-VS-Normal |
1.92450999999538E-05 |
| Other-VS-Normal |
9.74930000063878E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.01689784265591E-11 |
| Normal-vs-N1 |
2.00309768771945E-11 |
| N0-vs-N1 |
9.886100E-02 |
|
|
